Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding antiplatelet agent to OAC appears unnecessary

TCT 2018

Key clinical point: One year after a stent placement, an oral anticoagulant (OAC) alone may be sufficiently protective against major adverse thrombotic events.

Major finding: A measure that included cardiac events plus major bleeding showed an oral anticoagulant alone was noninferior to an OAC plus antiplatelet therapy.

Study details: Randomized, controlled trial of 696 patients.

Disclosures: Daiichi-Sankyo funded the trial. Dr. Nakano had no conflicts of interest. Dr. Gibson reported numerous financial ties to pharmaceutical companies, including Daiichi-Sankyo.

Read the article here.

Citation:

TCT 2018

This Week's Must Reads

Androgen Deprivation Therapy & Risk of Depression, Cancer; ePub 2019 Feb 12; Deka, Rose, et al

QOL in Patients with Low-Risk PC Treated with HRT, JAMA Oncol; ePub 2019 Feb 14; Bruner, et al

Hospital Competition & Prostate Cancer Outcomes, Cancer; ePub 2019 Feb 1; Aggarwal, et al

Insurance Status & Stage of Prostate Ca Diagnosis, Cancer Epidemiol; 2019 Apr; Ramirez, Morano, et al

Agent Orange Exposure & Prostate Ca Outcomes, J Urol; ePub 2019 Jan 8; Etheridge, et al